SARS-CoV-2 infection among patients with haematological disorders: Severity and one-month outcome in 66 Danish patients in a nationwide cohort study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Andreas Glenthøj, Københavns Universitet
  • ,
  • Lasse H. Jakobsen, Aalborg Universitet
  • ,
  • Henrik Sengeløv, Københavns Universitet
  • ,
  • Syed A. Ahmad, Københavns Universitet
  • ,
  • Kristian Qvist
  • ,
  • Annika Rewes, Syddansk Universitet
  • ,
  • Christian B. Poulsen, Sjællands Universitetshospital
  • ,
  • Ulrik M. Overgaard, Rigshospitalet
  • ,
  • Ingolf Mølle
  • ,
  • Marianne T. Severinsen, Aalborg Universitet
  • ,
  • Casper N. Strandholdt, South West Jutland Hospital
  • ,
  • Jack Maibom, Sjællands Universitetshospital
  • ,
  • Annette R. Kodahl, Syddansk Universitet
  • ,
  • Jesper Ryg, Syddansk Universitet
  • ,
  • Pernille Ravn, Københavns Universitet
  • ,
  • Isik S. Johansen, Syddansk Universitet
  • ,
  • Søren N. Helsø
  • Søren Jensen-Fangel
  • Jacek Kisielewicz, Southern Jutland Hospital
  • ,
  • Lothar Wiese, Sjællands Universitetshospital
  • ,
  • Marie Helleberg, Københavns Universitet
  • ,
  • Ole Kirk, Københavns Universitet
  • ,
  • Michael R. Clausen, Lillebaelt Hospital – University Hospital of Southern Denmark
  • ,
  • Henrik Frederiksen, Syddansk Universitet

Objectives: Patients with haematological disorders may be particularly vulnerable to respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, this is unknown. Methods: We conducted a prospective, nationwide study including 66 patients in follow-up at Danish haematology departments with a malignant or non-malignant haematological disorder and with verified SARS-CoV-2 infection. Outcomes were intensive care unit (ICU) admission and one-month survival rate. Results: Mean age was 66.7 years, 60.6% were males, 90.9% had comorbidity, and 13.6% had a BMI ≥ 30. The most frequent diagnoses were chronic lymphocytic leukaemia/lymphoma (47.0%), multiple myeloma (16.7%) and acute leukaemia/myelodysplastic syndrome (AL/MDS) (12.1%). Treatment for the haematological disease was ongoing in 59.1% of cases. Neutropenia was present in 6.5%, lymphopenia in 46.6% and hypogammaglobulinaemia in 26.3%. The SARS-CoV-2 infection was mild in 50.0%, severe in 36.4% and critical in 13.6%. After one month, 21.2% had been admitted to ICU, and 24.2% died. Mortality was highest in older patients, patients with severe/critical SARS-CoV-2 infection, high comorbidity score or high performance status score, purine analogue treatment and with AL/MDS. Although older patients and patients with comorbidities had the highest mortality rates, mortality was considerable among all haematological patients. Conclusion: Haematological patients with SARS-CoV-2 infection has a severe clinical course.

OriginalsprogEngelsk
BogserieEuropean Journal of Haematology
Vol/bind106
Nummer1
Sider (fra-til)72-81
Antal sider10
ISSN0902-4441
DOI
StatusUdgivet - jan. 2021

Se relationer på Aarhus Universitet Citationsformater

ID: 213845188